High Prevalence of Both Previous Infection with SARS-CoV-2 and Persistent Symptoms

References

1. 1.↵
   1. Buitrago-Garcia D,
   2. Egli-Gany D,
   3. Counotte MJ,
   4. et al

   . Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis. PLoS Med 2020;17:e1003346.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Oran DP,
   2. Topol EJ

   . Prevalence of asymptomatic SARS-CoV-2 infection: a narrative review. Ann Intern Med 2020; Jun 3:M20-3012.
3. 3.↵
   1. Lee S,
   2. Kim T,
   3. Lee E,
   4. et al

   . Clinical course and molecular viral shedding among aymptomatic and symptomatic patients with SARS-CoV-2 infection in a community treatment center in the Republic of Korea. JAMA Intern Med 2020;180:1447.

   OpenUrl
4. 4.↵
   1. McEvoy D,
   2. McAloon C,
   3. Collins A,
   4. et al

   . Relative infectiousness of asymptomatic SARS-CoV-2 infected persons compared with symptomatic individuals: a rapid scoping review. BMJ Open 2021;11:e042354.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Poletti P,
   2. Tirani M,
   3. Cereda D

   , ATS Lombardy COVID-19 Task Forceet al. Association of age with likelihood of developing symptoms and critical disease among close contacts exposed to patients with confirmed SARS-CoV-2 infection in Italy. JAMA Netw Open 2021;4:e211085.

   OpenUrl
6. 6.↵
   1. Ebell MH,
   2. Chupp C,
   3. Bentivegna M

   . A high proportion of SARS-CoV-2-infected university students are asymptomatic. J Fam Pract 2020;69:428–9.

   OpenUrlPubMed
7. 7.↵
   1. Chohan BH,
   2. Lavreys L,
   3. Mandaliya KN,
   4. et al

   . Validation of a modified commercial enzyme-linked immunoassay for detection of human immunodeficiency virus type 1 immunoglobulin G antibodies in saliva. Clin Diagn Lab Immunol 2001;8:346–8.

   OpenUrlPubMed
8. 8.↵
   1. MacMullan MA,
   2. Ibrayeva A,
   3. Trettner K,
   4. et al

   . ELISA detection of SARS-CoV-2 antibodies in saliva. Sci Rep 2020;10:20818.

   OpenUrlCrossRef
9. 9.↵
   1. Hettegger P,
   2. Huber J,
   3. Paßecker K,
   4. et al

   . High similarity of IgG antibody profiles in blood and saliva opens opportunities for saliva based serology. PloS One 2019;14:e0218456.

   OpenUrl
10. 10.↵
    1. Varadhachary A,
    2. Chatterjee D,
    3. Garza J,
    4. et al

    . Salivary anti-SARS-CoV-2 IgA as an accessible biomarker of mucosal immunity against COVID-19. MedRxiv 2020. Aug 11;2020.08.07.20170258. Preprint.
11. 11.↵
    1. Mak T,
    2. Saunders M

    . Mucosal and cutaneous immunity. In: The immune response—basic and clinical principles. New York: Academic Press; 2006. p. 583–609.
12. 12.
    1. Jureka AS,
    2. Silvas JA,
    3. Basler CF

    . Propagation, inactivation, and safety testing of SARS-CoV-2. Viruses 2020;12:622.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Youden WJ

    . Index for rating diagnostic tests. Cancer 1950;3:32–5.

    OpenUrlCrossRefPubMedWeb of Science
14. 14.↵
    1. Diggle PJ

    . Estimating Prevalence Using an Imperfect Test. Epidemiol Res Int 2011;2011:e608719.

    OpenUrl
15. 15.↵
    Centers for Disease Control and Prevention [Internet]. Interim guidelines for COVID-19 antibody testing. Centers for Disease Control and Prevention; 2020 [cited 2021 June 17]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests-guidelines.html.
16. 16.↵
    The New York Times [Internet]. Tracking coronavirus cases at U.S. colleges and universities. The New York Times; 2021 [cited 2021 June 17]. https://www.nytimes.com/interactive/2021/us/college-covid-tracker.html.
17. 17.↵
    1. Tilley K,
    2. Ayvazyan V,
    3. Martinez L,
    4. et al

    . A cross-sectional study examining the seroprevalence of severe acute respiratory syndrome coronavirus 2 antibodies in a university student population. J Adolesc Health 2020;67:763–8.

    OpenUrlPubMed
18. 18.↵
    1. Kianersi S,
    2. Ludema C,
    3. Macy JT,
    4. et al

    . A cross-sectional analysis of demographic and behavioral risk factors of severe acute respiratory syndrome coronavirus 2 seropositivity among a sample of U.S. college students. J Adolesc Health Off Health 2021;69:219–26.

    OpenUrl
19. 19.↵
    1. Vusirikala A,
    2. Whitaker H,
    3. Jones S,
    4. et al

    . Seroprevalence of SARS-CoV-2 antibodies in university students: Cross-sectional study, December 2020, England. J Infect 2021;83:104–11.

    OpenUrl
20. 20.↵
    1. Gostin LO,
    2. Shaw J,
    3. Salmon DA

    . Mandatory SARS-CoV-2 vaccinations in K-12 schools, colleges/universities, and businesses. JAMA 2021;326:25.

    OpenUrl
21. 21.↵
    1. Gibas C,
    2. Lambirth K,
    3. Mittal N,
    4. et al

    . Implementing building-level SARS-CoV-2 wastewater surveillance on a university campus. Sci Total Environ 2021;782:146749.

    OpenUrlCrossRef
22. 22.↵
    1. Rennert L,
    2. McMahan C,
    3. Kalbaugh CA,
    4. et al

    . Surveillance-based informative testing for detection and containment of SARS-CoV-2 outbreaks on a public university campus: an observational and modelling study. Lancet Child Adolesc Health 2021;5:428–36.

    OpenUrl
23. 23.↵
    ACHA [Internet]. ACHA recommends COVID-19 vaccination requirements for fall 2021. ACHA; [cited 2021 June 17]. https://www.acha.org/ACHA/About/ACHA_News/ACHA_Recommends_COVID-19_Vaccination_Requirements_for_Fall_2021.aspx.
24. 24.↵
    1. Lerner AM,
    2. Robinson DA,
    3. Yang L,
    4. et al

    . Toward understanding COVID-19 recovery: National Institutes of Health workshop on postacute COVID-19. Ann Intern Med 2021;174:999–1003.

    OpenUrl
25. 25.↵
    1. Havervall S,
    2. Rosell A,
    3. Phillipson M,
    4. et al

    . Symptoms and functional impairment assessed 8 months after mild COVID-19 among health care workers. JAMA 2021;325:2015–6.

    OpenUrlCrossRefPubMed